Truvestments Capital’s Dyne Therapeutics DYN Stock Holding History

Truvestments Capital’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.55K	Hold	295	–	–	﹤0.01%	854
2026 Q1	$5.35K	Hold	295	–	–	﹤0.01%	871
2025 Q4	$5.77K	Hold	295	–	–	﹤0.01%	785
2025 Q3	$3.73K	Hold	295	–	–	﹤0.01%	869
2025 Q2	$2.81K	Hold	295	–	–	﹤0.01%	800
2025 Q1	$3.09K	Hold	295	–	–	﹤0.01%	812
2024 Q4	$6.95K	Hold	295	–	–	﹤0.01%	659
2024 Q3	$10.6K	Buy	+295	New	+$11.7K	﹤0.01%	574
2024 Q2	–	Sell	-464	Closed	-$13.2K	–	367
2024 Q1	$13.2K	Hold	464	–	–	0.01%	477
2023 Q4	$6.17K	Hold	464	–	–	﹤0.01%	571
2023 Q3	$4.16K	Hold	464	–	–	﹤0.01%	526
2023 Q2	$5.22K	Hold	464	–	–	﹤0.01%	523
2023 Q1	$5.34K	Buy	+464	New	+$6.03K	﹤0.01%	503

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Truvestments Capital's DYN Position: Q2 2026 in Review

Truvestments Capital held its Dyne Therapeutics (DYN) position steady in Q2 2026 at 295 shares worth $6.55K. The position accounts for ﹤0.01% of the portfolio, ranked #854.

Truvestments Capital first reported a position in DYN in Q1 2023 and has held it in 13 quarters since. The position peaked at $13.2K in Q1 2024. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

Truvestments Capital held 295 shares of Dyne Therapeutics worth $6.55K as of Q2 2026.
Truvestments Capital left its Dyne Therapeutics share count unchanged in Q2 2026.
Dyne Therapeutics made up ﹤0.01% of Truvestments Capital's portfolio in Q2 2026, its #854 holding.
Truvestments Capital first reported a position in Dyne Therapeutics in Q1 2023 and has held it in 13 quarters since.
Truvestments Capital's Dyne Therapeutics position peaked at $13.2K in Q1 2024.
245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Truvestments Capital's 13F filing for Q2 2026, filed 12 Aug 2026.